Study: 60 Percent of Tuberous Sclerosis Complex Patients Who Used CBD Products Saw Significant Reduction of Seizures

A new study has found promising results in CBD oil used as a treatment for patients suffering from seizures—primarily people with Tuberous Sclerosis Complex.

Results from the trial showed that 60 percent of participants who used CBD products saw a clinically significant (80-100 percent) reduction in the frequency of their seizures.

The recent clinical study was conducted by renowned Mexico neurologist, Dr. Carlos G. Aguirre-Velazquez. Mexico’s advancements in medical cannabis made international headlines this summer after when the State of Mexico announced it would provide cannabidiol (CBD) oil to citizens.

The trial utilized THC-free CBD oil product Real Scientific Hemp Oil-X™ (RSHO-X™) by Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the U.S., which launched subsidiary HempMeds® Mexico this summer.

Dr. Stuart Titus, CEO of Medical Marijuana, Inc. said “We applaud Dr. Aguirre for his work in unveiling, like he did in this study, that not only is CBD effective in relieving seizures, but also exhibiting that CBD can be used over long periods of time without harm, compared to antiepileptic or broad-spectrum steroids that can have dangerous side effects if used for several years, including vision and damage to major organs.”

Patients with varying forms of epilepsy participated in the trial, with the majority having TSC, a genetic disorder characterized by the growth of noncancerous (benign tumors) in many parts of the body, including the brain, which can lead to convulsive crises. TSC affects 1 million people worldwide, 50,000 in the U.S. and 20,000 in Mexico.

Research targeted the reduction in frequency, intensity and duration of convulsive crises in people with tuberous sclerosis complex. Other factors observed in the study were quality of life, dependence on heavy prescription drugs and long-term sustainability of treatment with CBD.

Additionally, quality of life metrics such mood, appetite and cognition saw substantial increases among the patients using CBD. Finally, no serious side effects were reported, only mild ones such as drowsiness and increase in appetite, which eventually disappeared with the need to reduce the dose.

The study concludes that, “The experience of parents and patients with medicinal cannabis (CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary to TSC.”

Dr. Aguirre will present his findings to an online audience on Thursday, October 12, 2017 on a live event on the Por Grace Facebook.

This isn’t the first time CBD oil has been proven to reduce seizures. A 2017 study by Dr. Saul Garza Morales, pediatric researcher and neurologist in Mexico, found that 86 percent of the 29 child patients with extreme epilepsy experienced statistically significant (greater than 50%) reduction in motor seizures. Seventeen percent of the children were fully seizure free for a four-month period.

Nearly half of cannabidiol patients stop using traditional medicines according to a recent report on CBD oil user experience by Brightfield Group and HelloMD, who anticipate that the total cannabidiol market will reach $467 million in 2017.

“Each time new study results are published showing the positive effects of CBD on a new indication is a victory for showcasing the therapeutic benefits of CBD and people around the world suffering from a multitude of debilitating conditions,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.

Mexico legalized the cultivation, production, and use of cannabis products with less than one percent THC for medical use when President Pena Nieto signed a bill into law on June 19.

HempMeds® Mexico’s zero-THC product RSHO-X™ was the first-ever cannabis product to receive approval from the federal government of Mexico, COFEPRIS, for importation into the country. 

Trafficroots Analysis Pixel